Summary:

Oligomerix has developed a proprietary platform technology for drug discovery and biomarker development for central nervous system (CNS) disorders focused on neurodegeneration and dementias, and has discovered unique, highly differentiated drug-like small molecules that inhibit tau self-association into toxic oligomers.

 

Founders:

James Moe | Eliot Davidowitz

 

Headquarters:

White Plains, NY